Author

Abby E. Rudolph

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Effectiveness of a bivalent RSV prefusion F protein-based vaccine in individuals with and without atherosclerotic cardiovascular disease: a prespecified analysis of the DAN-RSV trial

Respiratory syncytial virus (RSV) is associated with an increased risk of cardiovascular (CV) events, particularly among individuals with pre-existing CV disease. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine demonstrated effectiveness against RSV-related hospitalization outcomes in the first season...

M. Pareek, M. Lassen, M. Yafasov et al. · European Heart Journal · 0 citations

Aug 2026

Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults.

BACKGROUND Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-associated respiratory illness, but data fro...

M. Lassen, S. Christensen, M. Yafasov et al. · NEJM Evidence · 1 citation

Open access Jul 2026

Modeling the public health impact of vaccination with Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula in the pediatric population aged 5-17 years at high risk of severe outcomes from COVID-19 in the United States.

INTRODUCTION This study evaluated the potential public health impact of receiving Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula, in the US pediatric population aged 5-17 years at high risk of severe outcomes from COVID-19. RESEARCH DESIGN AND METHODS A previously published static decision-tree model was...

A. Yehoshua, M. di Fusco, Abby E. Rudolph et al. · Expert Review of Vaccines · 0 citations